MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
1.206
-0.414
-25.54%
After Hours: 1.230 +0.024 +1.98% 16:15 09/29 EDT
OPEN
1.620
PREV CLOSE
1.620
HIGH
1.625
LOW
1.200
VOLUME
1.84M
TURNOVER
--
52 WEEK HIGH
10.99
52 WEEK LOW
1.200
MARKET CAP
27.36M
P/E (TTM)
-0.0939
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KPTI last week (0921-0925)?
Weekly Report · 1d ago
Weekly Report: what happened at KPTI last week (0914-0918)?
Weekly Report · 09/21 09:21
Karyopharm Issues Convertible Preferred Stock, Alters Capital Structure
TipRanks · 09/18 20:36
Weekly Report: what happened at KPTI last week (0907-0911)?
Weekly Report · 09/14 09:22
Karyopharm Faces Liquidity Crisis Under Forbearance Agreement
TipRanks · 09/11 12:18
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 09/11 12:06
Karyopharm, guarantors enter into forbearance agreement
TipRanks · 09/11 11:55
Karyopharm Therapeutics Signs Forbearance Agreement, Limited Waiver To Indentures For Additional Time To Advance Its Myelofibrosis Program; Did Not Pay $15.8M Due Under Sept. 10 Credit Agreement
Benzinga · 09/11 11:51
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.